Pharmacoeconomics Matthijs Versteegh 4/19/23 Pharmacoeconomics Matthijs Versteegh 4/19/23

The value of health in a cost-effectiveness analysis: theory vs practice

Read More

European Journal of Health Economics Matthijs Versteegh 8/4/22 European Journal of Health Economics Matthijs Versteegh 8/4/22

Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries

Read More

methods, Health Economics Matthijs Versteegh 7/30/21 methods, Health Economics Matthijs Versteegh 7/30/21

Distributional consequences of including survivor costs in economic evaluations distributional consequences of survivor costs in economic evaluations

Read More

methods, rare diseases, Pharmacoeconomics Matthijs Versteegh 2/19/21 methods, rare diseases, Pharmacoeconomics Matthijs Versteegh 2/19/21

Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision

Read More

methods, NTvG Matthijs Versteegh 8/18/20 methods, NTvG Matthijs Versteegh 8/18/20

Pharmaceutical pricing: what is reasonable?

Read More

methods, Pharmacoeconomics Matthijs Versteegh 5/27/19 methods, Pharmacoeconomics Matthijs Versteegh 5/27/19

Severity-Adjusted Probability of Being Cost Effective

Read More

methods, NTvG Matthijs Versteegh 4/3/19 methods, NTvG Matthijs Versteegh 4/3/19

Is verlies winst? Stoppen met TNF-α-blokkers

Read More

methods, Health Economics Matthijs Versteegh 10/1/18 methods, Health Economics Matthijs Versteegh 10/1/18

A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending

Read More

methods, European Journal of Health Economics Matthijs Versteegh 9/5/18 methods, European Journal of Health Economics Matthijs Versteegh 9/5/18

When is it too expensive? Cost-effectiveness thresholds and health care decision-making

Read More

methods, European Journal of Health Economics Matthijs Versteegh 9/9/16 methods, European Journal of Health Economics Matthijs Versteegh 9/9/16

From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare

Read More

quality of life, methods, Social Science & Medicine Matthijs Versteegh 8/5/16 quality of life, methods, Social Science & Medicine Matthijs Versteegh 8/5/16

Patient and general public preferences for health states: A call to reconsider current guidelines

Read More

quality of life, methods, European Journal of Health Economics Matthijs Versteegh 7/31/13 quality of life, methods, European Journal of Health Economics Matthijs Versteegh 7/31/13

Introducing the composite time trade-off: a test of feasibility and face validity

Read More

quality of life, methods, European Journal of Health Economics Matthijs Versteegh 7/31/13 quality of life, methods, European Journal of Health Economics Matthijs Versteegh 7/31/13

Time trade-off: one methodology, different methods

Read More

quality of life, methods, European Journal of Health Economics Matthijs Versteegh 7/31/13 quality of life, methods, European Journal of Health Economics Matthijs Versteegh 7/31/13

Time to tweak the TTO: results from a comparison of alternative specifications of the TTO

Read More

quality of life, methods, Health Economics Matthijs Versteegh 12/11/12 quality of life, methods, Health Economics Matthijs Versteegh 12/11/12

WOULD YOU RATHER BE ILL NOW, OR LATER?

Read More

quality of life, methods, Health & Quality of Life Outcomes, Health Economics Matthijs Versteegh 3/6/12 quality of life, methods, Health & Quality of Life Outcomes, Health Economics Matthijs Versteegh 3/6/12

LEAD TIME TTO: LEADING TO BETTER HEALTH STATE VALUATIONS?

Read More

Matthijs Versteegh 11/26/10 Matthijs Versteegh 11/26/10

Mapping onto Eq-5 D for patients in poor health

Read More